Jared A. Leff

Jared A. Leff

Auto-generated profile, based on publicly available information

Jared A. Leff

Department of Public Health, Weill Cornell Medical College, New York, New York

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
JMJake R. Morgan
Jake R. Morgan
BSBruce R. Schackman
Bruce R. Schackman
JLJared A. Leff
Jared A. Leff
BLBenjamin P. Linas
Benjamin P. Linas
AWAlexander Y. Walley
Alexander Y. Walley

19 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BLBenjamin P. Linas
Benjamin P. Linas
DBDevra M. Barter
Devra M. Barter
JLJared A. Leff
Jared A. Leff
SASabrina A. Assoumou
Sabrina A. Assoumou
JSJoshua A. Salomon
Joshua A. Salomon
BSBruce R. Schackman
Bruce R. Schackman
As highly effective hepatitis C virus (HCV) therapies emerge, data are needed to inform the development of interventions to improve HCV treatment rates. We used simulation modeling to estimate the impact of loss to follow-up on HCV treatment outcomes and to identify intervention strategies likely to provide good value for the resources invested in them. We used a Monte Carlo state-transition model to simulate a hypothetical cohort of chronically HCV-infected individuals recently screened positive for serum HCV antibody. We simulated four hypothetical intervention strategies (linkage to care; treatment initiation; integrated case management; peer navigator) to improve HCV treatment rates, varying efficacies and costs, and identified strategies that would most likely result in the best value for the resources required for implementation. Sustained virologic responses (SVRs), life expectancy, quality-adjusted life expectancy (QALE), costs from health system and program implementation perspectives, and incremental cost-effectiveness ratios (ICERs). We estimate that imperfect follow-up reduces the real-world effectiveness of HCV therapies by approximately 75%. In the base case, a modestly effective hypothetical peer navigator program maximized the number of SVRs and QALE, with an ICER compared to the next best intervention of $48,700/quality-adjusted life year. Hypothetical interventions that simultaneously addressed multiple points along the cascade provided better outcomes and more value for money than less costly interventions targeting single steps. The 5-year program cost of the hypothetical peer navigator intervention was $14.5 million per 10,000 newly diagnosed individuals. We estimate that imperfect follow-up during the HCV cascade of care greatly reduces the real-world effectiveness of HCV therapy. Our mathematical model shows that modestly effective interventions to improve follow-up would likely be cost-effective. Priority should be given to developing and evaluating interventions addressing multiple points along the cascade rather than options focusing solely on single points.

4 January 2012 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
BSBruce R. Schackman
Bruce R. Schackman
JLJared A. Leff
Jared A. Leff
DPDaniel Polsky
Daniel Polsky
BMBrent A. Moore
Brent A. Moore
DFDavid A. Fiellin
David A. Fiellin

5 May 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BLBenjamin P. Linas
Benjamin P. Linas
DBDevra M. Barter
Devra M. Barter
JMJake R. Morgan
Jake R. Morgan
MPMai T. Pho
Mai T. Pho
JLJared A. Leff
Jared A. Leff
AKArthur Y. Kim
Arthur Y. Kim
Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. Randomized trials, observational cohorts, and national health care spending surveys. 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). Lifetime. Payer. Sofosbuvir-based therapies, pegylated interferon–ribavirin, and no therapy. Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). The ICER of sofosbuvir-based treatment was less than $100 000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200 000 per QALY in treatment-naive noncirrhotic patients. The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100 000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. The analysis did not consider possible benefits of preventing HCV transmission. Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.

1 April 2009 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
BSBret J. Spier
Bret J. Spier
SLShane J. Larue
Shane J. Larue
TTThomas C. Teelin
Thomas C. Teelin
JLJared A. Leff
Jared A. Leff
LSLisa R. Swize
Lisa R. Swize
PPPatrick R. Pfau
Patrick R. Pfau

15 January 2019 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SMSean M. Murphy
Sean M. Murphy
KMKathryn E. McCollister
Kathryn E. McCollister
JLJared A. Leff
Jared A. Leff
XYXuan Yang
Xuan Yang
PJPhilip J. Jeng
Philip J. Jeng
BSBruce R. Schackman
Bruce R. Schackman
Not enough evidence exists to compare buprenorphine–naloxone with extended-release naltrexone for treating opioid use disorder. To evaluate the cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone. Cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in 8 U.S. inpatient or residential treatment programs. Study instruments. Adults with opioid use disorder. 24-week intervention with an additional 12 weeks of observation. Health care sector and societal. Buprenorphine–naloxone and extended-release naltrexone. Incremental costs combined with incremental quality-adjusted life-years (QALYs) and incremental time abstinent from opioids. Use of the health care sector perspective and a willingness-to-pay threshold of $100 000 per QALY showed buprenorphine–naloxone to be preferable to extended-release naltrexone in 97% of bootstrap replications at 24 weeks and in 85% at 36 weeks. Similar results were obtained with incremental time abstinent from opioids as an outcome and with use of the societal perspective. The base-case results were sensitive to the cost of the 2 treatments and the success of randomized treatment initiation. Relatively short follow-up for a chronic condition, substantial missing data, no information on patient out-of-pocket and social service costs. Buprenorphine–naloxone is preferred to extended-release naltrexone as first-line treatment when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone. National Institute on Drug Abuse, National Institutes of Health.